What are the indications for baclofen and its dosing guidelines for spasticity in adults and children, intrathecal therapy, alcohol withdrawal, and refractory hiccups, including dose adjustments for renal impairment?

Baclofen Indications and Dosing

Baclofen is FDA-approved for spasticity from multiple sclerosis and spinal cord disorders, with oral dosing starting at 5 mg three times daily and titrating up to 40-80 mg/day in divided doses, while intrathecal baclofen is reserved for severe refractory cases. 1

FDA-Approved Indications

Spasticity (Primary Indication)

Baclofen is indicated for spasticity resulting from:

• Multiple sclerosis - particularly for flexor spasms, concomitant pain, clonus, and muscular rigidity
• Spinal cord injuries and diseases - patients must have reversible spasticity where treatment aids in restoring residual function 1

Important contraindications: Baclofen is NOT indicated for skeletal muscle spasm from rheumatic disorders, and efficacy has NOT been established for stroke, cerebral palsy, or Parkinson's disease 1

Oral Baclofen Dosing

Adults - Spasticity

Starting dose: 5 mg three times daily

Titration schedule:

• Increase by 5 mg per dose every 3 days
• Typical effective range: 40-80 mg/day in divided doses (3-4 times daily)
• Maximum dose: 80 mg/day (some sources cite up to 100 mg/day)

The stepwise approach begins with least-invasive modalities (positioning, stretching, range of motion) before progressing to oral medications 2

Renal Impairment - Critical Dosing Adjustments

This is where most toxicity occurs. Baclofen is primarily renally excreted, making dose reduction essential:

• Moderate renal impairment (eGFR 30-60 mL/min/1.73m²): Reduce dose significantly
• Severe renal impairment (eGFR <30 mL/min/1.73m²) or dialysis: AVOID USE - even 5 mg/day can cause life-threatening toxicity 3, 4, 5, 6

Common pitfall: Prescribing standard doses to patients with renal dysfunction leads to accumulation and severe neurotoxicity, including encephalopathy, seizures, and respiratory depression requiring mechanical ventilation 3, 5

Intrathecal Baclofen (ITB)

Indication

Reserved for chronic spasticity (stroke >6 months, spinal cord injury, MS) that:

• Results in pain, poor skin hygiene, or decreased function
• Is refractory to oral medications at maximum tolerated doses
• Does not respond to botulinum toxin or other interventions 2, 7

ITB Dosing Protocol

Screening phase:

• Single bolus test dose to determine response
• Typical screening dose: 50-100 mcg

Initiation:

• Starting daily dose = 2× the effective bolus screening dose
• If prolonged response (>8 hours) or negative reactions, use the screening dose itself as starting daily dose
• Begin with 500 mcg/mL concentration 8

Titration:

• Spinal-origin spasticity: Increase 10-30% every 24 hours
• Cerebral-origin spasticity: Increase 5-15% every 24 hours
• Pediatric patients: Increase 5-15% every 24 hours
• Assess within 24 hours of each dose change 8

Oral baclofen weaning: Taper oral baclofen first, one drug at a time, after ITB begins 8

Off-Label Uses (Guideline-Supported)

Alcohol Use Disorder (AUD)

Indication: Promoting abstinence and preventing relapse in alcohol-dependent patients, particularly those with alcoholic liver disease (ALD) and cirrhosis 9

Dosing:

• Evidence supports doses up to 30 mg/day in cirrhotic patients
• French ANSM recommends not exceeding 80 mg/day for AUD
• High-dose studies (>100 mg) show controversial results 9

Evidence quality: Baclofen is the only alcohol pharmacotherapy tested in patients with significant liver disease. A 2023 Cochrane review found moderate-certainty evidence that baclofen reduces relapse risk (RR 0.87) and increases percentage of days abstinent, particularly among detoxified participants 10

Alcohol Withdrawal Syndrome (AWS)

Baclofen has been tested as an alternative to benzodiazepines for AWS, though benzodiazepines remain the gold standard 9. Baclofen may be considered when benzodiazepines are contraindicated, but evidence is limited.

Neuropathic Pain (Limited Role)

Rarely considered - only for refractory trigeminal neuralgia or neuropathic pain unresponsive to first-line agents (gabapentinoids, antidepressants) 11. Anecdotal evidence suggests potential benefit, but risks often outweigh benefits given better alternatives.

Chronic Hiccups

Used off-label for refractory hiccups, though extreme caution required in renal impairment - even 5 mg/day caused life-threatening toxicity in an ESRD patient 5

Critical Safety Considerations

Major Adverse Effects

• Sedation (most common - dose-limiting)
• Weakness (particularly problematic in stroke patients where spasticity aids function)
• Seizures (especially in patients with epilepsy or brain damage)
• Respiratory depression (21% in toxicity cases) 12
• Specific side effects: Fatigue, dizziness, somnolence, dry mouth, paresthesia, muscle spasms 10

Withdrawal Syndrome - Life-Threatening

Onset: 1-4 days after abrupt discontinuation

Manifestations:

• Severe psychiatric disturbances (up to 20.6%)
• Delirium and agitation
• Autonomic instability
• Seizures
• Hyperthermia
• Can be fatal if untreated 13, 12

Management: Rapid baclofen reinitiation consistently resolves symptoms 12

Toxicity Recognition

Presentation at doses ≥300 mg:

• CNS depression (68%)
• Seizures (36%)
• Respiratory depression (21%) requiring mechanical ventilation in 54.5% 12

Management: Primarily supportive care; hemodialysis effective for removal in renal patients 3, 4, 6. Recovery occurs in 97.7% with appropriate management 12

Special Populations

Contraindicated or use extreme caution:

• Patients where spasticity maintains upright posture or balance 1
• Epilepsy patients (monitor EEG - deterioration reported) 1
• Pediatric patients <12 years (safety not established) 1
• Elderly with renal impairment - highest risk group for toxicity

Drug interactions: CNS effects additive with alcohol and other CNS depressants 1